Project Grant R21AI194544
Award Date
6/23/25
Completion Date
5/31/27
Dollars Obligated
$516K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,071 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a universal transmission blocking vaccine against malaria. The goal is to create a vaccine targeting conserved mosquito-stage antigens that can prevent infection across multiple Plasmodium species that cause malaria. Key aspects...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $813,160 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The goal is to create vaccines that provide effective immune protection against malaria infection and reduce disease transmission. The project will evaluate protective efficacy of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $244,440 to Albert Einstein College of Medicine to conduct research exploring the role of cytolytic ZEB2+ memory CD4+ T cells in providing protection against the liver stage of malaria infection. The goal is to gain insights into the cellular immune determinants associated with natural clinical immunity to malaria, which could inform...
This $147,656 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to understand the role of transmembrane proteins in the cell division process of the malaria parasite Plasmodium falciparum. The award, effective January 22, 2025 through October 31, 2027, will enable the integration of biochemical and super-resolution microscopy approaches to decipher...
This federal Project Grant award of $205,125.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding research at Hennepin Healthcare Research Institute (HHRI) to investigate the impact of microbial exposure on the efficacy of Plasmodium vaccines. The project aims to utilize a mouse model that better mimics human immune responses to define the immune response to Plasmodium vaccination and test an...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,174,636 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU). The funding supports research to optimize the structural features of the antimalarial drug candidate ELQ-596, with the goal of developing a next generation of ELQs for once-monthly oral malaria prophylaxis in humans. The research aims to simplify dosing, improve compliance,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $711,993 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Boston Medical Center Corporation (BMC) on June 11, 2025. The grant supports research to understand the effects of Mycobacterium tuberculosis (MTB) disease on HIV-1 pathogenesis, immunity, and persistence in people living with HIV. Specifically, the project will assess how MTB disease impacts the HIV-1 immune response,...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover the targets of naturally acquired protection against severe Plasmodium falciparum malaria and develop them as novel blood-stage vaccine candidates. The award, totaling $708,202 and effective from December 2024 through November 2029, will support research at Brown University to identify the parasite...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $738,445 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Drexel University to develop an mRNA-based multivalent malaria vaccine. The project aims to optimize mRNA vaccine-induced antibody-mediated and cell-mediated immune responses targeting pre-erythrocytic and blood-stage malaria parasites. Specifically, the grant will support the design, production, and evaluation of mRNA vaccine candidates...
The federal Project Grant award of $700,288 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research to identify genetic factors associated with the development of sexual stages (gametocytes) in the malaria parasite Plasmodium falciparum. The project combines expertise in gametocyte biology, advanced computational genomics, and phenotype comparisons with clinical...